Log in Book a Demo

US Pharma & Biotech Infectious Diseases - PPC Market Share Analysis May 2025

Leveraging Adthena’s Whole Market View, this analysis explores recent trends in Google Ads for the US Infectious Diseases category from the last month. Our Data Analyst, Ask Arlo provides commentary on key findings.

Market Exposure

Share of Clicks for top 10 US Pharma & Biotech Infectious Diseases brands

Here are the Top 10 competitors in the industry by Share of Clicks for the last month.

See more data
Share of Clicks - Last month
Domain Share of clicks
uqora.com 16.58
mavyret.com 9.13
admired.com 7.15
paxlovid.com 7.06
cabenuva.com 5.88
hellowisp.com 4.65
epclusa.com 4.41
dovato.com 3.75
symtuzahcp.com 3.06
apretudeonline.com 2.85
others 35.48

Copyright © Adthena. All rights reserved.

In the PPC landscape, ‘others’ dominate with 35.48% click share. ‘Uqora.com’ follows at 16.58%, while ‘Mavyret.com’ holds 9.13%. ‘Admired.com’ and ‘Paxlovid.com’ capture 7.15% and 7.06%, respectively.

Market Exposure

Share of Spend for the top 10 US Pharma & Biotech Infectious Diseases brands

Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month. 

See more data
Share of Spend - Last Month
Date uqora.com biktarvy.com cabenuva.com epclusa.com symtuzahcp.com dovato.com apretude.com mavyret.com sunlencahcp.com sunlenca.com
2025/05/01 8.13% 10.81% 1.45% 5.07% 1.42% 9.37% 1.11% 12.01% 7.53% 7.92%
2025/05/02 8.16% 6.71% 19.84% 4.22% 1.43% 1.9% 1.63% 8.82% 3.91% 3.75%
2025/05/03 0% 9.75% 11.7% 2.06% 2.02% 7.55% 1.46% 16.27% 4.23% 6.65%
2025/05/04 5.92% 7.3% 16.05% 2.3% 2.44% 9.43% 3.14% 5% 3.52% 5.1%
2025/05/05 0% 8% 10.58% 1.72% 5.47% 8.03% 4.46% 12.68% 5.13% 5.91%
2025/05/06 16.23% 4.97% 9.27% 2.08% 1.97% 4.11% 4.99% 7.43% 5.2% 3.47%
2025/05/07 7.53% 6.24% 7.65% 4.82% 2.49% 4.25% 3.22% 12.05% 3.88% 1.67%
2025/05/08 9.81% 9.78% 15.37% 1.85% 2.16% 1.99% 1.6% 4.68% 4.98% 3.53%
2025/05/09 0% 11.78% 11.31% 3.75% 3.23% 3.15% 4.03% 16.03% 4.31% 1.95%
2025/05/10 0% 7.81% 8.68% 3.82% 3.51% 9.79% 4.2% 13.04% 6.39% 6.27%
2025/05/11 5.9% 4.41% 13.52% 3.04% 7.22% 1.84% 13.3% 7.12% 2.36% 1.37%
2025/05/12 3.16% 9.95% 7.9% 8.73% 2.56% 6.88% 1.37% 15.18% 6.13% 4.17%
2025/05/13 2.57% 6.25% 5.29% 4.16% 3.07% 4.59% 1.46% 8.29% 7.22% 7.36%
2025/05/14 11.1% 10.06% 2.65% 2.25% 2.41% 8.91% 7.57% 7.05% 6.11% 4.64%
2025/05/15 1.41% 11.69% 11.44% 2.17% 7.07% 6.89% 7.01% 10.75% 3.83% 3.56%
2025/05/16 6.11% 10.18% 3.36% 9.58% 2.63% 2.94% 3.23% 14.12% 7.35% 6.32%
2025/05/17 8.96% 4.64% 22.73% 2.72% 9.72% 1.25% 9.77% 1.64% 4.02% 5.39%
2025/05/18 10.06% 7.84% 8.29% 7.57% 3.03% 0.85% 2.94% 7.68% 4.72% 6.3%
2025/05/19 9.01% 6.42% 4.28% 6.87% 3.72% 2.09% 2.78% 7% 5.47% 7.94%
2025/05/20 9.46% 4.59% 10.08% 4.25% 3.55% 3.5% 3.02% 13.77% 4.92% 7.42%
2025/05/21 7.92% 6.83% 15.82% 5.55% 3.6% 2.88% 2.7% 4.92% 3.96% 5.68%
2025/05/22 12.91% 7.23% 7.57% 0.73% 0.91% 3.54% 4.15% 4.94% 6.04% 6.14%
2025/05/23 12.7% 8.84% 10.48% 7.1% 1.68% 5.91% 2.01% 3.69% 5.13% 4.86%
2025/05/24 4.63% 4.23% 12.59% 4.03% 12.36% 13.93% 12.38% 4.93% 2.77% 3.39%
2025/05/25 10.32% 4.03% 6.16% 3.18% 13.82% 6.27% 2.58% 4.27% 3.41% 3.82%
2025/05/26 5.1% 5.7% 12.57% 5.98% 5.88% 5.65% 3.65% 11.38% 4.8% 6.3%
2025/05/27 11.97% 5.5% 15.25% 1.45% 1.82% 6.09% 1.39% 1.93% 4.31% 5.59%
2025/05/28 2.19% 7.32% 16.68% 6.08% 3.71% 12.01% 4.16% 4.74% 5.48% 6.57%
2025/05/29 9.37% 7.67% 11.04% 2.67% 2.92% 5.93% 4.28% 1.24% 5.91% 6.08%
2025/05/30 0% 6.42% 10.54% 4.83% 2.07% 13.71% 5.37% 16.08% 4.33% 1.93%
2025/05/31 7.53% 7.39% 6.83% 6.1% 6.02% 5.99% 5.95% 5.7% 4.32% 1.48%

Copyright © Adthena. All rights reserved.

In May 2025, Uqora.com saw fluctuating ad spend, peaking at 16.23 on May 6. Biktarvy.com maintained steady spending, while Cabenuva.com experienced a significant spike on May 17. Epclusa.com and Symtuzahcp.com had moderate fluctuations. Dovato.com and Apretude.com showed varied trends, with notable peaks. Mavyret.com had a strong start, peaking mid-month. Sunlencahcp.com and Sunlenca.com displayed consistent spending, with minor variations. The month concluded with diverse spending patterns across domains.

Market Exposure

Competitor Count for US Pharma & Biotech Infectious Diseases

Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month. 

See more data
Competitor Count - Last month
Date Competitor Count
2025/05/01 57
2025/05/02 61
2025/05/03 58
2025/05/04 66
2025/05/05 56
2025/05/06 69
2025/05/07 59
2025/05/08 60
2025/05/09 57
2025/05/10 58
2025/05/11 65
2025/05/12 59
2025/05/13 69
2025/05/14 64
2025/05/15 65
2025/05/16 62
2025/05/17 64
2025/05/18 63
2025/05/19 68
2025/05/20 68
2025/05/21 63
2025/05/22 64
2025/05/23 62
2025/05/24 61
2025/05/25 64
2025/05/26 63
2025/05/27 69
2025/05/28 64
2025/05/29 70
2025/05/30 66
2025/05/31 71

Copyright © Adthena. All rights reserved.

May saw a dynamic shift in distinct advertisers, starting at 57 and peaking at 71. The month concluded with a notable increase, indicating heightened competition.

Campaign Efficiency

Market Loss & Market Gains for US Pharma & Biotech Infectious Diseases

Here we’re looking at the Top 10 biggest industry movers by market share gains and losses for the last 30 days.

See more data
Market Loss & Market Gains - Last month
Name Market Trend
hellowisp.com 3.75%
uqora.com 3.19%
epclusa.com 1.14%
dovato.com 0.82%
prevnar20.com 0.8%
dovatohcp.com -0.89%
cabenuva.com -1.08%
apretude.com -1.11%
goodbye-uti.com -1.46%
mavyret.com -3.81%

Copyright © Adthena. All rights reserved.

Mavyret.com saw a significant drop of 3.81%, while hellowisp.com surged by 3.75%. Uqora.com also rose by 3.19%, contrasting with goodbye-uti.com’s decline of 1.46%.

Campaign Efficiency

US Pharma & Biotech Infectious Diseases Share of Impressions

Take a look at the Top 10 competitors in the industry by Share of Impressions over the last month.

See more data
Date uqora.com mavyret.com hellowisp.com cabenuva.com apretude.com epclusa.com symtuzahcp.com dovato.com apretudeonline.com admired.com
2025/05/01 27.1% 9.4% 7.77% 0.51% 0.66% 2.59% 1.08% 3.25% 2.38% 11.61%
2025/05/02 18.5% 12.58% 7.69% 6.63% 1.56% 3.67% 1.5% 1.48% 3.43% 3.67%
2025/05/03 0% 29.56% 0.04% 7.34% 1.5% 1.04% 2.13% 4.86% 6.4% 0%
2025/05/04 15.14% 5.31% 4.15% 8.56% 3.1% 1.8% 2.15% 3.17% 6% 11.36%
2025/05/05 0% 19.05% 0.05% 6.15% 4.66% 1.01% 4.84% 4.86% 7.59% 7%
2025/05/06 26.61% 7.29% 6.67% 4.28% 3.28% 0.48% 1.42% 2.24% 5.53% 6.65%
2025/05/07 19.17% 14.48% 0.01% 2.5% 2.19% 3.27% 2.33% 1.97% 6.64% 9.59%
2025/05/08 20.07% 5.35% 0.03% 4.91% 1.81% 1.13% 2.58% 1.87% 4.37% 13.38%
2025/05/09 0% 24.21% 0.82% 5.23% 4.22% 3.62% 3.54% 2.64% 2.44% 0%
2025/05/10 0% 21.93% 0.02% 3.37% 3.89% 2.72% 3.77% 6.11% 2.02% 13.11%
2025/05/11 11.24% 7.31% 2.26% 10.63% 10.18% 2.57% 5.64% 1.22% 9.53% 9%
2025/05/12 6% 22.79% 0.03% 2.53% 1.34% 8.69% 1.99% 3.43% 2.68% 17.99%
2025/05/13 4.69% 12.47% 4.71% 3.04% 1.34% 4.05% 2.82% 3.31% 3.2% 4.69%
2025/05/14 22.94% 6.58% 4.6% 2.09% 5.39% 0.65% 1.93% 3.53% 1.49% 13.76%
2025/05/15 2.73% 14.94% 0.38% 9.19% 6.95% 1.39% 6.85% 7.24% 1.35% 2.73%
2025/05/16 18.66% 14.96% 1.26% 2.46% 2.73% 7.6% 2.15% 2.39% 1.66% 4.66%
2025/05/17 17.82% 2.27% 5.95% 18.36% 8.71% 2.28% 8.78% 1.31% 2.56% 0%
2025/05/18 17.14% 9.14% 6.86% 3.34% 2.14% 7.34% 2.73% 0.79% 1.56% 13.71%
2025/05/19 18.25% 7.7% 7.3% 2.82% 1.98% 5.2% 2.7% 1.41% 2.5% 7.3%
2025/05/20 15.42% 18.43% 9.25% 4.92% 2.38% 3.35% 3.24% 3.77% 3.51% 9.25%
2025/05/21 15.47% 5.6% 9.29% 4.54% 2.27% 4.79% 2.64% 2.69% 4.43% 12.38%
2025/05/22 21.48% 6.07% 8.59% 2.69% 3.27% 0.3% 0.82% 2.01% 1.65% 8.59%
2025/05/23 25.83% 3.65% 12.92% 4.09% 1.79% 6.63% 1.58% 3.18% 2.69% 9.69%
2025/05/24 11.13% 6.06% 4.45% 11.24% 10.39% 4.15% 10.86% 9.47% 0.59% 4.45%
2025/05/25 21.56% 5.07% 2.78% 2.17% 1.74% 2.49% 12.01% 6.31% 11.45% 5.45%
2025/05/26 8.66% 15.16% 8.67% 4.78% 3.37% 5.89% 4.43% 4.29% 3.01% 12.99%
2025/05/27 25.71% 2.32% 11.03% 6.56% 1.34% 0.88% 1.7% 3.29% 2.7% 11.02%
2025/05/28 4.88% 7.15% 11.09% 8.5% 3.15% 8.8% 4.49% 6.56% 2.14% 4.88%
2025/05/29 20.79% 0.89% 0.37% 4.7% 3.02% 1.67% 2.35% 4.88% 3.77% 7.91%
2025/05/30 0% 28.84% 0.04% 6.16% 5.75% 5.6% 2.49% 7.34% 1.21% 0%
2025/05/31 14.11% 7.83% 7.12% 6.13% 5.7% 5.5% 5.12% 5.08% 3.01% 0%

Copyright © Adthena. All rights reserved.

Uqora.com led May with fluctuating impressions, peaking at 27.1% and dipping to 2.73%. Mavyret.com saw a significant spike on May 3rd at 29.56%. By month’s end, Uqora.com maintained dominance, while Mavyret.com surged again.

Campaign Efficiency

Google Text Ad Copy Insights & Creative Trends for US Pharma & Biotech Infectious Diseases

Ever wondered how your rivals’ ads are doing? Here we can see the top-performing ads in the industry over the last month.

See more data
  1. 1
    What Is PrEP? Read Facts Here - Learn About PrEP Today

    Learn About A Medication Used To Prevent HIV. Discover More At The Official Patient Site. Review Important Safety Information ...

  2. 2
    FDA-Approved HIV Treatment - HIV Antiretroviral Treatment

    Learn If You May Be Eligible To Save On Treatment. Visit The Official Patient Site Now.

  3. 3
    Hepatitis C Treatment Option - Treatment Cost & Coverage

    No Symptoms? Still Take Hep C Seriously. Discuss Treatment With A Healthcare Professional.

  4. 4
    SUNLENCA® (lenacapavir) | Official Patient Website https://www.sunlenca.com

    Find Important Safety Info And Dosing Information On The Official Patient Website. See A Treatment Option And Ask Your Healthcare Professional If SUNLENCA® Is Right For You. Safety & Side Effects. How To Take.

  5. 5
    Antiretroviral HIV Option - Single-Tablet Regimen

    Rapidly Starting HIV-1 Patients on ARV? Investigators Present Trial Data: Watch Video Now

Copyright © Adthena. All rights reserved.

In the competitive landscape of pharmaceuticals, top-performing PPC ads reveal a focus on HIV and Hepatitis C treatments. Apretude and Dovato emphasize education and savings, while Mavyret highlights the seriousness of Hepatitis C. Sunlenca and Symtuza offer detailed safety and treatment information, underscoring patient empowerment.

Frequently Asked Questions

Customer Success Stories

the7stars Case study: PPC campaign Optimization

the7stars case study: Achieving Google Ads PPC campaign optimization​ with Adthena

Leveraging Adthena's comprehensive insights, the7stars and their lottery client optimized their PPC campaigns and organic strategies, resulting in substantial cost savings and improved campaign performance. Read case study
Sage Case study: Brand protection strategy

Sage case study: 75% decrease in CPCs with Adthena

Sage, a leading UK software provider, used Adthena’s brand protection strategy to curb rising CPC costs. By identifying brand infringements and optimizing spend, they effectively strengthened their brand protection strategy and increased ROI.Read case study

Vodafone case study: Driving click share and sales with strategic insights from Adthena

Vodafone used Adthena data to optimize results from the launch of the Samsung S22 product. Combining Adthena’s Strategic Insights with Google Smart Bidding, Vodafone was able to maintain a flexible strategy that leveraged both manual and automated bidding. Leveraging Adthena’s Search Term Opportunities report also allowed Vodafone to implement 27 keyword terms across their business line, driving an increase in revenue at a positive ROAS.Read case study

Get the full picture

See this data specific to your brand performance

The data on this page is just a sample of the billions of data points we hold at Adthena. The insights generated by Ask Arlo, leverage real-time GenAI to answer questions about your search data.

Our search consultants can introduce you to Whole Market View data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the locations that you need monitoring.

Related reports

US
Pharma & Biotech

US Pharmacology

US
Pharma & Biotech

US Research and Development

US
Pharma & Biotech

US Pulmonology

UK
Pharma & Biotech

UK Pharmacology